IDEAS home Printed from https://ideas.repec.org/a/eee/jhecon/v69y2020ics0167629618309020.html
   My bibliography  Save this article

The impact of cannabis access laws on opioid prescribing

Author

Listed:
  • McMichael, Benjamin J.
  • Van Horn, R. Lawrence
  • Viscusi, W. Kip

Abstract

While recent research has shown that cannabis access laws can reduce the use of prescription opioids, the effect of these laws on opioid use is not well understood for all dimensions of use and for the general United States population. Analyzing a dataset of over 1.5 billion individual opioid prescriptions between 2011 and 2018, which were aggregated to the individual provider-year level, we find that recreational and medical cannabis access laws reduce the number of morphine milligram equivalents prescribed each year by 11.8 and 4.2 percent, respectively. These laws also reduce the total days’ supply of opioids prescribed, the total number of patients receiving opioids, and the probability a provider prescribes any opioids net of any offsetting effects. Additionally, we find consistent evidence that cannabis access laws have different effects across types of providers, physician specialties, and payers.

Suggested Citation

  • McMichael, Benjamin J. & Van Horn, R. Lawrence & Viscusi, W. Kip, 2020. "The impact of cannabis access laws on opioid prescribing," Journal of Health Economics, Elsevier, vol. 69(C).
    • Handle: RePEc:eee:jhecon:v:69:y:2020:i:c:s0167629618309020
    DOI: 10.1016/j.jhealeco.2019.102273
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0167629618309020
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.jhealeco.2019.102273?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Abby Alpert & David Powell & Rosalie Liccardo Pacula, 2017. "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," NBER Working Papers 23031, National Bureau of Economic Research, Inc.
    2. Williams, Jenny & Bretteville-Jensen, Anne Line, 2014. "Does liberalizing cannabis laws increase cannabis use?," Journal of Health Economics, Elsevier, vol. 36(C), pages 20-32.
    3. Kim, J.H. & Santaella-Tenorio, J. & Mauro, C. & Wrobel, J. & Cerda, M. & Keyes, K.M. & Hasin, D. & Martins, S.S. & Li, G., 2016. "State medical marijuana laws and the prevalence of opioids detected among fatally injured drivers," American Journal of Public Health, American Public Health Association, vol. 106(11), pages 2032-2037.
    4. Benjamin Hansen & Keaton Miller & Caroline Weber, 2020. "Early Evidence On Recreational Marijuana Legalization And Traffic Fatalities," Economic Inquiry, Western Economic Association International, vol. 58(2), pages 547-568, April.
    5. Abby Alpert & David Powell & Rosalie Liccardo Pacula, 2018. "Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids," American Economic Journal: Economic Policy, American Economic Association, vol. 10(4), pages 1-35, November.
    6. Rosalie L. Pacula & David Powell & Paul Heaton & Eric L. Sevigny, 2015. "Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil is in the Details," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 34(1), pages 7-31, January.
    7. repec:aph:ajpbhl:10.2105/ajph.2017.304059_5 is not listed on IDEAS
    8. Yu-Wei Luke Chu, 2015. "Do Medical Marijuana Laws Increase Hard-Drug Use?," Journal of Law and Economics, University of Chicago Press, vol. 58(2), pages 481-517.
    9. Powell, David & Pacula, Rosalie Liccardo & Jacobson, Mireille, 2018. "Do medical marijuana laws reduce addictions and deaths related to pain killers?," Journal of Health Economics, Elsevier, vol. 58(C), pages 29-42.
    10. Livingston, M.D. & Barnett, T.E. & Delcher, C. & Wagenaar, A.C., 2017. "Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015," American Journal of Public Health, American Public Health Association, vol. 107(11), pages 1827-1829.
    11. Rosalie Liccardo Pacula & David Powell, 2018. "A Supply‐Side Perspective On The Opioid Crisis," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 37(2), pages 438-446, March.
    12. Thomas C. Buchmueller & Colleen Carey, 2018. "The Effect of Prescription Drug Monitoring Programs on Opioid Utilization in Medicare," American Economic Journal: Economic Policy, American Economic Association, vol. 10(1), pages 77-112, February.
    13. Wen, Hefei & Hockenberry, Jason M. & Cummings, Janet R., 2015. "The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances," Journal of Health Economics, Elsevier, vol. 42(C), pages 64-80.
    14. Ashley C. Bradford & W. David Bradford, 2018. "The Impact of Medical Cannabis Legalization on Prescription Medication Use and Costs under Medicare Part D," Journal of Law and Economics, University of Chicago Press, vol. 61(3), pages 461-487.
    15. Halvorsen, Robert & Palmquist, Raymond, 1980. "The Interpretation of Dummy Variables in Semilogarithmic Equations," American Economic Review, American Economic Association, vol. 70(3), pages 474-475, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Mathur, Neil K. & Ruhm, Christopher J., 2023. "Marijuana legalization and opioid deaths," Journal of Health Economics, Elsevier, vol. 88(C).
    2. Johanna Catherine Maclean & Keshar M. Ghimire & Lauren Hersch Nicholas, 2021. "Marijuana legalization and disability claiming," Health Economics, John Wiley & Sons, Ltd., vol. 30(2), pages 453-469, February.
    3. Mir M. Ali & Chandler McClellan & Ryan Mutter & Daniel I. Rees, 2023. "Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata," Health Economics, John Wiley & Sons, Ltd., vol. 32(2), pages 277-301, February.
    4. Carrieri, Vincenzo & Madio, Leonardo & Principe, Francesco, 2020. "Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs," Journal of Health Economics, Elsevier, vol. 74(C).
    5. Lucas Marín Llanes & Hernando Zuleta, 2022. "Myths of drug consumption decriminalization: effects of Portuguese decriminalization on violent and drug use mortality," Documentos CEDE 20328, Universidad de los Andes, Facultad de Economía, CEDE.
    6. Sabia, Joseph J. & Dave, Dhaval & Alotaibi, Fawaz & Rees, Daniel I., 2024. "The effects of recreational marijuana laws on drug use and crime," Journal of Public Economics, Elsevier, vol. 234(C).
    7. Cameron M. Ellis & Martin F. Grace & Rhet A. Smith & Juan Zhang, 2022. "Medical cannabis and automobile accidents: Evidence from auto insurance," Health Economics, John Wiley & Sons, Ltd., vol. 31(9), pages 1878-1897, September.
    8. Rahi Abouk & Keshar M. Ghimire & Johanna Catherine Maclean & David Powell, 2023. "Pain Management and Work Capacity: Evidence From Workers’ Compensation and Marijuana Legalization," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 42(3), pages 737-770, June.
    9. Shyam Raman & Johanna Catherine Maclean & W. David Bradford & Coleman Drake, 2023. "Recreational cannabis and opioid distribution," Health Economics, John Wiley & Sons, Ltd., vol. 32(4), pages 747-754, April.
    10. Ahomäki, Iiro & Pitkänen, Visa & Soppi, Aarni & Saastamoinen, Leena, 2020. "Impact of a physician-targeted letter on opioid prescribing," Journal of Health Economics, Elsevier, vol. 72(C).
    11. Natali, Ilaria, 2024. "Economic Opportunity and Opioid Regulation: the Case of Codeine in France," TSE Working Papers 24-1563, Toulouse School of Economics (TSE).
    12. Davide Fortin, 2024. "Legalizing cannabis in Colorado: Displacement or market expansion?," French Stata Users' Group Meetings 2024 03, Stata Users Group.
    13. Beasley, W. Jason & Dundas, Steven J., 2024. "Recreational cannabis dispensary access effects on prescription opioid use and mortality," Regional Science and Urban Economics, Elsevier, vol. 108(C).
    14. George Dranitsaris & Carlo DeAngelis & Blake Pearson & Laura McDermott & Bernd Pohlmann-Eden, 2021. "Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis," Applied Health Economics and Health Policy, Springer, vol. 19(4), pages 537-544, July.
    15. Amanda C. Cook & E. Tice Sirmans & Brenda Wells, 2024. "Does the legalisation of cannabis for medicinal use impact private health insurer prescription drug expenditures?," The Geneva Papers on Risk and Insurance - Issues and Practice, Palgrave Macmillan;The Geneva Association, vol. 49(1), pages 212-226, January.
    16. Jiebing Wen & Hefei Wen & J. S. Butler & Jeffery C. Talbert, 2021. "The impact of medical and recreational marijuana laws on opioid prescribing in employer‐sponsored health insurance," Health Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 989-1000, May.
    17. Thomas Lebesmuehlbacher & Rhet A. Smith, 2021. "The effect of medical cannabis laws on pharmaceutical marketing to physicians," Health Economics, John Wiley & Sons, Ltd., vol. 30(10), pages 2409-2436, September.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Junxing Chay & Seonghoon Kim, 2022. "Heterogeneous health effects of medical marijuana legalization: Evidence from young adults in the United States," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 269-283, February.
    2. Pohl, R. Vincent, 2018. "Time Trends Matter: The Case of Medical Cannabis Laws and Opioid Overdose Mortality," MPRA Paper 88219, University Library of Munich, Germany.
    3. Cameron M. Ellis & Martin F. Grace & Rhet A. Smith & Juan Zhang, 2022. "Medical cannabis and automobile accidents: Evidence from auto insurance," Health Economics, John Wiley & Sons, Ltd., vol. 31(9), pages 1878-1897, September.
    4. Kalbfuss, Jörg & Odermatt, Reto & Stutzer, Alois, 2024. "Medical marijuana laws and mental health in the United States," Health Economics, Policy and Law, Cambridge University Press, vol. 19(3), pages 307-322, July.
    5. Chakraborty Avinandan & Doremus Jacqueline & Stith Sarah, 2021. "The effects of recreational cannabis access on labor markets: evidence from Colorado," IZA Journal of Labor Economics, Sciendo & Forschungsinstitut zur Zukunft der Arbeit GmbH (IZA), vol. 10(1), pages 1-86, January.
    6. Alice M. Ellyson & Jevay Grooms & Alberto Ortega, 2022. "Flipping the script: The effects of opioid prescription monitoring on specialty‐specific provider behavior," Health Economics, John Wiley & Sons, Ltd., vol. 31(2), pages 297-341, February.
    7. Jenny Williams & Rosalie Liccardo Pacula & Rosanna Smart, 2019. "De Facto or De Jure? Ethnic Differences in Quit Responses to Legal Protections of Medical Marijuana Dispensaries," NBER Working Papers 25555, National Bureau of Economic Research, Inc.
    8. Mir M. Ali & Chandler McClellan & Ryan Mutter & Daniel I. Rees, 2023. "Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata," Health Economics, John Wiley & Sons, Ltd., vol. 32(2), pages 277-301, February.
    9. Sabia, Joseph J. & Dave, Dhaval & Alotaibi, Fawaz & Rees, Daniel I., 2024. "The effects of recreational marijuana laws on drug use and crime," Journal of Public Economics, Elsevier, vol. 234(C).
    10. Keshar M. Ghimire & Johanna Catherine Maclean, 2020. "Medical marijuana and workers' compensation claiming," Health Economics, John Wiley & Sons, Ltd., vol. 29(4), pages 419-434, April.
    11. Christopher J. Ruhm, 2018. "Deaths of Despair or Drug Problems?," NBER Working Papers 24188, National Bureau of Economic Research, Inc.
    12. Meinhofer, Angélica & Witman, Allison E., 2018. "The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion," Journal of Health Economics, Elsevier, vol. 60(C), pages 177-197.
    13. Petrova, Olga & Gray, Natallia, 2021. "The effects of medical marijuana laws on birth outcomes: Evidence from early adopting U.S. states," Economic Analysis and Policy, Elsevier, vol. 69(C), pages 68-82.
    14. Christopher J. Ruhm, 2019. "Shackling the Identification Police?," Southern Economic Journal, John Wiley & Sons, vol. 85(4), pages 1016-1026, April.
    15. Chu, Yu-Wei Luke & Gershenson, Seth, 2018. "High times: The effect of medical marijuana laws on student time use," Economics of Education Review, Elsevier, vol. 66(C), pages 142-153.
    16. Powell, David & Pacula, Rosalie Liccardo & Jacobson, Mireille, 2018. "Do medical marijuana laws reduce addictions and deaths related to pain killers?," Journal of Health Economics, Elsevier, vol. 58(C), pages 29-42.
    17. Alex Hollingsworth & Coady Wing & Ashley C. Bradford, 2022. "Comparative Effects of Recreational and Medical Marijuana Laws on Drug Use among Adults and Adolescents," Journal of Law and Economics, University of Chicago Press, vol. 65(3), pages 515-554.
    18. David Beheshti, 2019. "Adverse health effects of abuse‐deterrent opioids: Evidence from the reformulation of OxyContin," Health Economics, John Wiley & Sons, Ltd., vol. 28(12), pages 1449-1461, December.
    19. Chu, Yu-Wei Luke & Townsend, Wilbur, 2019. "Joint culpability: The effects of medical marijuana laws on crime," Journal of Economic Behavior & Organization, Elsevier, vol. 159(C), pages 502-525.
    20. Carrieri, Vincenzo & Madio, Leonardo & Principe, Francesco, 2020. "Do-It-Yourself medicine? The impact of light cannabis liberalization on prescription drugs," Journal of Health Economics, Elsevier, vol. 74(C).

    More about this item

    Keywords

    Cannabis; Marijuana; Opioids;
    All these keywords.

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
    • K19 - Law and Economics - - Basic Areas of Law - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:jhecon:v:69:y:2020:i:c:s0167629618309020. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/inca/505560 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.